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The rising proportion of melanomas diagnosed at an early pathologic stage is commonly ascribed to better public education.
However in the US SEER program of cancer registration it has been found that the rates for in situ melanomas are closely related
by a log linear relationship to the incidence of invasive melanomas and that this relationship is unrelated to calendar year or
gender or patient age. This relationship is suﬃciently strong to leave little room for other factors. The relationship may be diﬀerent
in populations with diﬀerent melanoma rates and responses to them. It is suggested that the results are due to variations within
populations of individual response to melanoma cell proliferation.
1.Introduction
Over recent decades in many prosperous white populations
the incidence of malignant melanoma of the skin has
been rising. Concomitant with this, there has been a shift
towards earlier diagnosis, with a consequent improvement
in prognosis. This has been ascribed by numerous authors
to improved public and professional education [1–4].
In contrast, it has been shown, in the US population-
based cancer registration system, that there is a systematic
proportional relationship between incidence rates for in situ
melanoma and invasive melanoma in males and females at
all ages and over a long time period [5].
This paper explores the relationship between the inci-
dence rate data for in situ and invasive melanoma further.
It shows that the proportionate relationship between the
in situ and invasive rates is very powerful and leaves room
for only a small contribution by any diagnostic or other
historical change. An explanation for the link could be found
in variations between individuals in resistance to developing
melanomas.
2.DataandMethods
The SEER (Statistics Epidemiology and End Results) Pro-
gram of the U.S. National Cancer Institute (NCI) covers a
group of nine geographic areas within the contiguous US
that provide population-based cancer registration from 1975
to present. Data from the years 1975 to 2004 for malignant
melanoma of the skin were downloaded from the SEER
website [6].
This study was restricted to white people. The cases
analyzed were restricted to ﬁrst diagnoses and were all
histologically conﬁrmed. Cases were classiﬁed at the time
of diagnosis as in situ (limited to the epidermis), localized
invasive, regional spread, and distant spread. The localized,
regional, and distant cases were combined as invasive. The
cases unstaged were not analyzed further.
The age range for both males and females was 15–84 in
14 ﬁve-year- age groups.
The association between incidence rate of in situ and
of invasive melanoma is modeled by Poisson maximum-
likelihood regression. Goodness-of-ﬁt of each model was
assessed by a pseudo-R-squared measure that compared a
model with just the intercept to a model with intercept and
coeﬃcient [7].
ThedataweretabulatedusingSEERStatsoftware[8]and
analyzed using Stata 9.0. [9].
3. Results
Rates for males and females for single years 1975–2004
and the age range 15–84 are shown for in situ and invasive
melanoma for the nine geographic SEER areas combined in2 Dermatology Research and Practice
Table 1: Parameters of linear models ﬁtted to ln. rates for in situ and invasive melanomas. The parameters are shown for males and females
for the entire period (84 data pairs for each gender) and for each period separately (14 data pairs).
Gender Period Coeﬃcient ucl lcl Constant ucl lcl Pseudo R2
Male 1975–2004 1.700 1.722 1.677 −14.891 −14.806 −14.977 0.940
Female 1975–2004 2.097 2.138 2.055 −15.760 −15.627 −15.893 0.867
Male 1975–79 2.275 2.607 1.944 −17.358 −16.415 −18.300 0.844
Male 1980–84 1.777 1.947 1.607 −15.708 −15.168 −16.248 0.868
Male 1985–89 1.702 1.796 1.609 −15.101 −14.775 −15.427 0.935
Male 1990–94 1.594 1.659 1.529 −14.537 −14.298 −14.777 0.966
Male 1995–99 1.472 1.516 1.427 −13.937 −13.762 −14.112 0.980
Male 2000–04 1.378 1.412 1.344 −13.419 −13.282 −13.557 0.986
Female 1975–79 1.766 2.186 1.347 −15.750 −15.627 −15.893 0.578
Female 1980–84 1.96 2.257 1.662 −15.944 −15.116 −16.772 0.703
Female 1985–89 1.733 1.914 1.552 −14.905 −14.375 −15.434 0.783
Female 1990–94 1.613 1.734 1.491 −14.247 −13.882 −14.613 0.873
Female 1995–99 1.542 1.631 1.453 −13.880 −13.592 −14.168 0.906
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Figure 1: Rates at the time of diagnosis for invasive and in situ
melanoma by single calendar years, US SEER program.
Figure 1. The rates are similar in males and females, while,
as expected, over time the in situ r a t e sr i s em u c hf a s t e rt h a n
the invasive.
In Table 1 log linear models are shown for males and
females relating the in situ and invasive rates for all discrete
populations,deﬁnedbygender,agefrom15to84andperiod,
from 1975–79 to 2000–2004. The conﬁdence limits are very
close and the coeﬃcients of variation are close to one.
T h em o d e l sa n dr a t e sa r es h o w ni nFigure 2.
Similar models are also shown in the table for the
separate 5-year time periods from 1975–1979 to 2000–2004.
The coeﬃcients decline slowly, apparently as the in situ rates
approach a maximum (Figure 1). The coeﬃcients of the
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Figure 2: In situ rates at diagnosis plotted against invasive rates at
diagnosis for six ﬁve-year-time periods (1975–2004) and fourteen
ﬁve year age groups (15–190–80–84), and linear models (Table 1)
(Males and Females, SEER [6]).
Figure 3 shows the set of 84 observed rates for in situ
melanoma and estimated rates derived from the single
two-parameter log linear equation and the set of observed
invasive rates for males. The picture for females is similar.
This is a demonstration (not a test, as there is only one data
set) of the power of the relationship and its indiﬀerence to
time or age.
4. Discussion
The connection between log incidence and log invasive
rate for malignant melanoma is a substantial feature of
the disease. The real distinction maybe between the tumors
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Figure 3: Comparison between observed rates in males for in
situ melanoma and model rates derived from the single log linear
equation for the whole period (Table 1) giving in situ rates derived
from invasive rates for single years 1975–2004.
have. But the precise value of the relationship may be an
artifact produced by the original choice invasive rates as the
independent variable and in situ rates as the dependent. For
instance,acuttingpointwithinthescaleofBreslowthickness
might be even better.
It is probable that resistance to the multiplication of
malignant melanoma cells varies between people, and the
systematic relationship between in situ and invasive rates
reﬂects this. In a benign environment, those with the poorest
resistance will be the only ones to get a melanoma and
will present with the most advanced disease; in a severe
environment, stronger resistors will get the disease, but be
able to keep it in situ.
The data reported here are combined from nine SEER
geographic populations scattered the United States from
Detroit to Hawaii. Their separate examination could be
helpful. It is possible that in other populations, such as those
of Australia and New Zealand with diﬀerent melanoma rates
and diﬀerent responses, other relationships will be found.
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